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ABSTRACT/ SUMMARY:  
Tumor dormancy is considered one of the major unsolved questions in cancer biology. Understanding the 
mechanisms responsible for maintaining and interrupting dormancy would be a major step towards preventing 
overt metastatic disease. Increasing evidence points to tissue trauma and subsequent wound healing as 
contributing events in escape from dormancy. In this review, we outline relevant aspects of the wound healing 
process, and relate this to mechanisms of tumor dormancy and metastatic progression. In addition to important 
findings in epidemiological and experimental studies, more direct evidence of such a link has recently been 
presented. These results can have major implications for treatment and prevention of cancer. 
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1. 1 Wound healing and cancer 
The process of wound healing is a carefully orchestrated series of partly overlapping events, involving multiple 
local and systemic changes, all with the intent to restore tissue homeostasis, regain function and protect from 
infection. Whether the wound is caused by a traumatic event or deliberately inflicted by surgery, successful 
healing is crucial, as demonstrated by the major healt  issues caused by deficient wound healing capacity seen in 
diabetic patients amongst others. The similarities b tween the composition of the granulation tissue in healing 
wounds and the stroma of tumors led to the seminal publication by Harold Dvorak, stating that tumors ae
“wounds that do not heal” [1]. Clinical observations of increased susceptibility for cancer development at sites of 
chronic inflammation, such as ventricular cancer in H. Pylori-infected gastric mucosa, hepatocellular cancer in 
patients with chronic viral hepatitis and colorectal ncer in inflammatory bowel disease, demonstrate he 
interplay between cancer development and local inflammation[2]. The increased risk of breast and colorectal 
cancer in obesity, a condition of chronic elevation of inflammatory mediators, supports the existence of a 
systemic effect[3]. One of the first experimental evid nces that infliction of wounds leads to tumor frmation 
was the Fisher brothers’ series of experimental factors influencing the formation of hepatic metastases, where 
both liver resection (local trauma effect) and laparotomy (systemic effect) caused an increase in liver m tastasis 
formation[4, 5]. Later, in a model of tumor development after injection with Rous sarcoma virus, Bissel and 
coworkers demonstrated that tumors developed at a site di tant from inoculation only if a wound was inflicted at 
that site. If the animal was treated with an anti-iflammatory drug, tumor development was prevented[6]. The 















sophisticated models, such as melanoma cells in wounded translucent zebrafish, where live imaging revealed 
rapid divergence of wound healing activated neutrophils to nearby pre-neoplastic cells causing increased 
proliferation and full malignant transformation[7]. Recently, outgrowth of dormant tumors at a distant 
anatomical site in response to surgery and wound healing was robustly demonstrated in a murine model system 
of immune-restricted tumor growth. Inflammatory monocytes were implicated as the functional mediators, and 
the effect was counteracted by perioperative administrat on of an NSAID.[8] 
2.1 Tumor dormancy overview 
The concept of tumor dormancy, where cancer cells from a primary tumor disseminate early and enter a state of 
dormancy with a potential to cause late relapses is recognized in many cancers[9]. Autopsy studies have re ealed 
dormant tumors in a large number of people dying from other causes, reviewed in [10, 11]. When comparing the 
prevalence of microscopic tumors of the thyroid andbreast in autopsy studies to overt thyroid and breast cancer 
it is clear that for most people, the cancer remains dormant throughout life [12, 13]. Most research in the field of 
tumor dormancy has been focused on breast cancer, noto ious for late relapses even decades after apparently 
successful treatment of small primary tumors[14]. Studies of the relapse pattern of breast cancer in several large 
patient series have revealed a biphasic distribution of relapses, consistent with the existence of a dormant 
phase[15, 16]. The mechanisms causing and maintainig dormancy in the clinical setting are not definitely 
established. Models suggest multiple factors such as inability to recruit blood vessels[17], immune 
suppression[18], entrance into cell cycle arrest[19], microenvironmental growth restriction[20] and 
autophagy[21]. Likewise, the means by which cancer cells can escape from dormancy are not fully elucidate , 
but as wound healing has been demonstrated to accelerate cancer growth [22], and epidemiological studies have 
revealed a peak in relapses after surgical procedures[23, 24] the theory that some factors in wound healing can 
mediate escape from tumor dormancy is highly relevant. This is especially unsetteling when considering the fact 
that surgery, where cancer-stimulating wound healing may take place in the presence of occult, dormant 
micrometastases, remains primary treatment in many c cer forms. In addition to wound healing, cancer surgery 
also includes anesthesia and analgesia, as well as potentially perioperative hypothermia and hypovolemia, factors 
that may add to cancer growth stimulation. Details on the scientific evidence for such effects were recently 
comprehensively reviewed [25]. When studying the phases of wound healing, with inflammation, immune 















makes biological sense. Each phase of wound healing is outlined below with corresponding evidence from 
studies linking the involved mechanisms to escape from tumor dormancy. 
3.1 The phases of wound healing and their effects on tumor dormancy and metastasis 
3.1.1 The immediate response 
The immediate response, initiated by tissue and vessel trauma, rapidly leads to blood clotting to stop local 
hemorrhage. The blood clot, predominantly consisting of cross-linked fibrin and platelets, previously considered 
merely a temporary physical sealing of the wound, is now known to have several biological functions [27]. 
When endothelial integrity is disrupted, underlying collagen and von Willebrand factor are exposed and activate 
platelets in the blood stream. Activated platelets r lease alpha-granules, packed with over 300 growth factors and 
cytokines including platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), transforming growth factor beta (TGF-β) and matrix metalloproteinases 
(MMPs) [28, 29]. This cocktail of factors is intended to attract inflammatory cells, stimulate cell proliferation, 
vessel formation and degradation of matrix. If a microscopic tumor is suspended in dormancy by insufficient 
blood supply, this release of VEGF may constitute an “angiogenic switch” allowing escape from dormancy by 
stimulated angiogenesis[17, 30] and VEGF levels have been correlated with disease progression[31]. In vitro and 
in vivo studies have demonstrated both improved wound healing nd enhanced breast cancer cell colony 
formation by addition of platelet lysate [32, 33, 34]. The main effect of platelet activation on cancer s ems to be 
to promote invasion and metastasis. TGF-β is one of the most potent drivers of epithelial to mesenchymal 
transition (EMT), a process where cells of epithelial origin gain a more mesenchymal phenotype by losing 
polarity and cell-to-cell adhesions, downregulating E-cadherin and upregulating vimentin, thus becoming more 
mobile[35]. This is needed for keratinocytes to re-epithelialize the wound surface, but when adopted by cancer 
cells, especially in combination with leakier capillaries due to VEGF and matrix degradation by MMPs, 
promotes invasion and metastasis. Fig. 1a. 
3.1.2 Inflammation 
Chemoattractants released from platelets, together with complement activation leads to the next phase: 
inflammation. First to arrive are the neutrophils[36], followed by macrophages[37] and lymphocytes. 
Neutrophils secrete prostaglandin E2 (PGE2), and reactive oxygen species (ROS), further fueling inflammation 















inflammatory cytokines such as IL-6, and bacterial lipopolysaccharides (LPS) [39]. PGE2 is prominent among 
the inflammatory mediators that also exert tumor-sustaining effects [40], and elevated levels have been 
associated with poor prognosis in various malignancies, including breast, lung and colon [41, 42, 43, 44].
Among the physiological functions of PGE2 in wound healing are stimulation of proliferation, migration a d 
angiogenesis, cancer cells may utilize these effects to increase metastatic efficiency [40]. PGE2 is also  key 
mediator of cancer immune evasion by suppressing type I interferons and T-cell mediated tumor elimination and 
altering dendritic cell maturation and ability to secrete cytokines [45]. The cancer promoting role of PGE2 is 
further supported by the beneficial effect on recurrence free survival associated with cyclooxygenase (COX) -
inhibitors such as aspirin [46, 47]. A central role for neutrophils in escape from dormancy was supported by an 
in vivo study of LPS-induced inflammation in mice with disseminated dormant carcinoma cells. By upregulation 
of EMT-factor Zeb1, dormancy was interrupted and macroscopic metastases developed. Neutrophil depletion 
abrogated this effect [48].  ROS and reactive nitrogen species can have tumorigenic effects by directly damaging 
DNA as well as by modifying proteins involved in critical steps of cell-cycle checkpoint control, DNA-repair 
and apoptosis [49]. In addition, ROS stimulates activ tion of COX-2 and thereby increases PGE2-production 
[38]. A large number of cells, including fibroblasts, keratinocytes, endothelial cells and macrophages, produce 
IL-6 in response to infection and tissue damage [50]. The classical effects of IL-6 includes induction f fever, 
hepatocyte stimulation to produce acute phase proteins such as C-reactive protein (CRP) and release of 
adrenocorticotropic hormone [51, 52], mainly mediated via signal transducer and activator of transcription 3 
(STAT3). In cancer cells, IL-6 has been demonstrated to induce EMT [53, 54], promote proliferation and 
survival, and serum levels are a negative prognosticator of both relapse and response to therapy in breast and 
kidney cancer patients [55, 56, 57]. CRP and IL-6 leve s have been demonstrated to be negative prognostic 
markers in most cancers [58, 59, 60, 61, 62].  
Recent evidence suggests an important role of macrophages in early breast cancer dissemination; intra-epithelial 
macrophages were observed in early murine mammary lesions, corresponding to ductal carcinoma in situ in 
humans, depletion of macrophages at these early stages significantly reduced later metastatic development [63]. 
The macrophages in wound healing are predominantly of he M2, or alternately activated type [64], which s 
considered to be mainly pro-tumorigenic, as compared to the classically activated M1 macrophages, potent 
killers of microorganisms and cancer cells [65]. The M2 macrophages have a central role in promoting 
angiogenesis, tissue remodeling and repair by producing growth factors including VEGF, EGF, TGF-β and 















urokinase-type plasminogen activator (uPA) and its receptor uPAR [65]. In a model of carcinoma cell growth, 
high uPAR was demonstrated to induce escape from dor ancy by upregulating the mitogenic extracellular 
regulated kinase (ERK) 1/2, and blocking the apoptotic and growth-arresting activity of p38 via regulation of 
fibronectin fibril assembly [66]. Production of PGE2 and accumulation of neutrophils and macrophages is partly 
counteracted by activation of the hypothalamic-pituitary-adrenal (HPA) axis, which takes place within minutes 
of wounding and results in release of cortisol and drenaline [67]. However, this also results in release of T-
regulatory cells (Tregs), and can thus aid in cancer immune evasion [68]. The physiological rationale for this 
immunomodulatory effect in wounding probably is to avoid excessive tissue damage and autoimmunity [69, 70]. 
VEGF, in addition to its angiogenic effects, also contributes to immunosuppression by inhibiting dendritic cell 
maturation of hematopoietic progenitor cells [71] allowing for accumulation of myeloid-derived suppressor cells 
[72]. Silencing VEGF in vivo has been shown to unleash an antitumor immune response leading to tumor 
eradication [73] and VEGF blockade to decrease the number of Tregs [74]. Fig. 1b. 
3.1.3 Proliferation, migration and contraction 
Proliferating, sprouting blood vessels are a key comp nent to wound healing by supplying nutrients, cells and 
growth factors. While endothelial cells of stable bood vessels produce thrombospondin-1 (TSP-1), which 
induces breast cancer cell quiescence, sprouting vessels not only loses TSP-1, but are also rich in tumor-
promoting factors such as periostin and TGF-β, thus sparking metastatic outgrowth as has been demonstrated 
both in vitro and in vivo [75]. Metastasis incompetent cancer cells have been d monstrated to create a metastasis 
refractory microenvironment by endocrine and paracrine secretion of prosaposin, a peptide that increases 
expression of TSP-1. Highly metastatic cells have significantly lower levels of this peptide [76]. Bone-marrow 
specific genetic deletion of TSP-1 increased metastasi  formation in distant organs in vivo, an effect that was 
abrogated by bone marrow transplant from TSP-1+ donors. In the same study, pharmacological induction of 
TSP-1 dramatically suppressed metastasis [77].  Activated neutrophils have been shown to participate in 
degrading TSP-1 in the lungs, further facilitating escape from dormancy [78]. The bone marrow is considered a 
dormancy supportive niche; this may be mediated by TGF-β and dependent on the EMT associated receptor 
tyrosine kinase Axl [79]. Increased Axl activity has been associated with a differentiated and prolifeating 
cellular phenotype which can switch to an invasive, non-proliferative, therapy resistant and dormant phenotype 
when the Axl activity is reduced[80, 81]. In prostate cancer cells, Axl has been demonstrated to be upreg lated 















the wound margins are stimulated to migrate into the wound and proliferate, mainly by TGF-β which is secreted 
from activated platelets in the early phase and later by several cell types [83]. In keratinocytes, migration is 
preceded by a partial epithelial-to-mesenchymal-transition, EMT, where the keratinocytes downregulate cell-to-
cell contact and hemidesmosomes, rearrange the cytoskeleton, secrete proteases  and extend lamellipodia t  be 
able to degrade connective tissue and move into the granulation tissue of the wound [49]. These mechanisms, 
when applied to cancer cells, facilitate invasion and dissemination and thus metastatic seeding. In cancer, the 
EMT is more frequently complete, characterized by complete loss of cell-to-cell adhesions and expression of 
mesenchymal marker proteins like vimentin, resembling early embryogenesis, as opposed to the partial EMT in 
wound healing keratinocytes[84]. For cancer cells to regain their proliferative potential, mesenchymal to 
epithelial transition, MET, is also necessary as the decision between EMT/MET state determines if the cell 
should “go or grow” [85]. In physiological wound healing, the keratinocytes, by an as yet undetermined signal, 
reverts to the epithelial phenotype at completion of w und healing leading to the final phase, resoluti n and 
remodeling [86]. Parallel to these events, fibroblasts are recruited to the wound site and deposit extracellular 
matrix proteins. A few days after injury, fibroblasts differentiate to myofibroblasts with expression of α-smooth 
muscle actin, responsible for wound contraction [87]. Fibroblasts and myofibroblasts can be recruited by cancer 
cells to secrete growth factors, aid in invasion and in generating a cancer-supporting stroma which immune cells 
and cytotoxic agents have difficulties penetrating [88, 89, 90]. Fig. 1c. 
3.1.4 Resolution and remodeling 
In normal wound healing, the inflammation and proliferation, by not fully understood mechanisms, resolves 
when tissue regeneration is completed. The early collagen III-dominated matrix is gradually replaced by collagen 
I in dense bundles forming stiff scar tissue[91]. It has been demonstrated, in vivo and in vitro, that a collagen I-
rich, fibrotic environment can be a determinant of cytoskeletal reorganization in dormant tumor cells, inducing 
proliferation and metastasis formation through β1-integrin downstream signaling, an effect that wasrepealed by 
blocking β1-integrin [92].  
The resolution phase also includes regrowth of appendages, MMPs degrades and remodels the extracellular 
matrix to form organized collagen and proteoglycans, neutrophils and macrophages undergo apoptosis or return 
to the vasculature [27]. Failure of this resolution, with sustained inflammation, due to chronic infection, 
















4.1 Conclusions and future perspectives 
As outlined above, many of the signaling molecules and cells involved in wound healing have also been 
demonstrated to play a role in escape from tumor dormancy and development of metastases. Connecting the dots 
is a first step to being able to target this interplay in order to prevent overt, incurable, metastatic disease. An 
epidemiological study by our group identified a subgroup of breast cancer patients with early recurrences 
presenting with multiple, similar sized metastases, indicative of a synchronized onset of growth [94]. Post-
surgery wound healing may constitute such a synchronizing signal. To study the effect of surgery on metastatic 
relapse, we proceeded to study the relapse pattern fter delayed breast reconstruction. This revealed  peak in 
relapses 18 months after reconstruction[23], similar to what has been observed after primary breast cancer 
surgery[15]. The height of the peak correlated with the extent of surgery, thus demonstrating a dose-re ponse 
relationship suggesting a causal connection[23]. The systemic impact of surgery on metastatic growth is also 
demonstrated in a study of patients presenting withstage IV disease, where locoregional surgical treatm nt of the 
breast tumor resulted in improved local control but also a significant reduction in distant progression-free 
survival [95].When considering targeting dormant cancer cells in the clinical setting one faces several obstacles. 
Treatment to maintain cancer cell dormancy throughot the patient’s life might appear attractive. However, 
patients’ adherence to therapy, which inevitably comes with side effects, to prevent an uncertain risk of 
recurrence is limited, as has been demonstrated for adjuvant hormonal therapy in early-stage breast cancer 
patients [96]. In this study, full adherence to presc ibed treatment was 49%. Inducing escape from dorancy in 
order to make the cells sensitive to treatment is a r ky method if we are not certain to be able to kill all cancer 
cells. At present, the most plausible approach would be to selectively prevent escape from dormancy at times 
when the risk is elevated, such as at surgery or during subsequent wound healing. Indeed, a short term burst of 
angiogenic factors has been demonstrated in vivo to be able to push a dormant tumor into progressiv growth, 
after this, lower levels sufficed to maintain this phenotype [97]. Still, these findings remain to be confirmed. The 
peri-operative time as a window of opportunity to prevent escape from dormancy, is further supported by 
epidemiologic observations of improved disease-free survival and overall survival when non-steroidal anti-
inflammatory drugs are used intraoperatively in conservative breast cancer surgery [98]. A randomized clinical 
trial investigating this is ongoing [99]. Identifying and targeting dormant tumor cells, to prevent metastatic 
relapse, is one of the great, unsolved questions in cancer research today, the answer to which could lea  to 
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Fig. 1 a) The immediate response. Activated platelets releas  growth factors (vascular-endothelial growth factor 















matrix metalloproteinases (MMPs). These factors recruit inflammatory cells and stimulate vessel sprouting, re-
epithelialization and degradation of matrix, but may also stimulate pre-existing dormant tumor cells at a distant 
site for proliferation and migration. EMT=epithelial to mesenchymal transition. b) Inflammation. Neutrophils 
and macrophages secrete growth factors, cytokines, reactive oxygen species (ROS) and prostaglandin E2 
(PGE2), fueling an inflammatory response in the wound and surrounding tissues. Systemic levels increase, and 
these factors are also known to be able to stimulate proliferation and migration of tumor cells. Macrophage-
derived uPA has been demonstrated to induce escape from dormancy by upregulating mitogenic extracellular 
regulated kinase (ERK) 1/2 and downregulating the growth arresting, pro-apoptotic p38. Systemic release of 
cortisol and adrenaline stimulates T-regulatory cells and can thus aid in cancer immune evasion. The rec ptor 
tyrosine kinase Axl is downregulated in proliferating metastases. c) Proliferation, migration and contraction. 
Sprouting vessels produce tumor-promoting factors such as TGF-β. In order to re-epithelialize the wound 
surface, keratinocytes undergo a partial EMT. Fibroblasts generate scar-tissue and can aid cancer cells in 
invasion and migration. d) Resolution and remodeling. I  normal tissue, inflammation and proliferation resolves 
by unknown mechanisms when tissue is regenerated, inflammatory cells return to the vasculature. A stiff, 
fibrotic environment can determine cytoskeletal reorganization through β1-integrin downstream signaling, 
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